Study of a thrombopoietin receptor agonist, for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin.

This study will evaluate sustained virological response rates as well as evaluate the safety and tolerability of the study drug as compared with placebo.

You may be eligible to participate in this study if you:

• Have evidence of HCV infection
• Are a candidate for peginterferon alfa-2b and ribavirin combination anti-viral therapy

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.